Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright decreased their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, March 4th.
View Our Latest Report on AEMD
Aethlon Medical Stock Performance
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Featured Stories
- Five stocks we like better than Aethlon Medical
- Financial Services Stocks Investing
- MarketBeat Week in Review – 6/3 – 6/7
- Investing in Travel Stocks Benefits
- Geron Corporation: FDA Approval Fuels Stock Price Surge
- Trading Stocks: RSI and Why it’s Useful
- Intel’s Secret Plan for a Double-Digit Stock Rally Revealed
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.